This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015 Dec 3;373(23):2289-90.

doi: 10.1056/NEJMc1509753.

Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan

Brian Claggett¹, Milton Packer, John J V McMurray, Karl Swedberg, Jean Rouleau, Michael R Zile, Pardeep Jhund, Martin Lefkowitz, Victor Shi, Scott D Solomon; PARADIGM-HF Investigators

Affiliations

PMID: 26630151
DOI: 10.1056/NEJMc1509753

Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan

Brian Claggett et al. N Engl J Med. 2015.

. 2015 Dec 3;373(23):2289-90.

doi: 10.1056/NEJMc1509753.

Authors

Brian Claggett¹, Milton Packer, John J V McMurray, Karl Swedberg, Jean Rouleau, Michael R Zile, Pardeep Jhund, Martin Lefkowitz, Victor Shi, Scott D Solomon; PARADIGM-HF Investigators

Affiliation

¹ Brigham and Women's Hospital, Boston, MA.

PMID: 26630151
DOI: 10.1056/NEJMc1509753

No abstract available

PubMed Disclaimer

Similar articles

[Update on the clinical application of valsartan/sacubitril in patients with heart failure].
[No authors listed] [No authors listed] Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Jun 24;45(6):538-541. doi: 10.3760/cma.j.issn.0253-3758.2017.06.018. Zhonghua Xin Xue Guan Bing Za Zhi. 2017. PMID: 28648033 Chinese. No abstract available.
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
Sangaralingham LR, Sangaralingham SJ, Shah ND, Yao X, Dunlay SM. Sangaralingham LR, et al. Circ Heart Fail. 2018 Feb;11(2):e004302. doi: 10.1161/CIRCHEARTFAILURE.117.004302. Circ Heart Fail. 2018. PMID: 29453287 Free PMC article.
[Sacubitril/valsartan receives European approval].
[No authors listed] [No authors listed] MMW Fortschr Med. 2015 Dec 14;157(21-22):84. doi: 10.1007/s15006-015-7627-5. MMW Fortschr Med. 2015. PMID: 26960881 German. No abstract available.
Sacubitril/Valsartan: potential treatment for paediatric heart failure.
Das BB, Scholl F, Vandale B, Chrisant M. Das BB, et al. Cardiol Young. 2018 Sep;28(9):1077-1081. doi: 10.1017/S1047951118001014. Epub 2018 Jul 6. Cardiol Young. 2018. PMID: 29979147 Review.
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Ansara AJ, Kolanczyk DM, Koehler JM. Ansara AJ, et al. J Clin Pharm Ther. 2016 Apr;41(2):119-27. doi: 10.1111/jcpt.12363. Epub 2016 Mar 18. J Clin Pharm Ther. 2016. PMID: 26992459 Review.

See all similar articles

Cited by

Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
Sokos GG, Raina A. Sokos GG, et al. Vasc Health Risk Manag. 2020 Jan 16;16:41-51. doi: 10.2147/VHRM.S197291. eCollection 2020. Vasc Health Risk Manag. 2020. PMID: 32021227 Free PMC article. Review.
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.
Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Docherty KF, et al. JACC Heart Fail. 2020 Oct;8(10):800-810. doi: 10.1016/j.jchf.2020.06.020. JACC Heart Fail. 2020. PMID: 33004114 Free PMC article. Review.
Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
Książczyk M, Lelonek M. Książczyk M, et al. Heart Fail Rev. 2020 May;25(3):393-402. doi: 10.1007/s10741-019-09879-x. Heart Fail Rev. 2020. PMID: 31713710 Free PMC article. Review.
Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis.
Seidelmann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, Folsom AR, Rimm EB, Willett WC, Solomon SD. Seidelmann SB, et al. Lancet Public Health. 2018 Sep;3(9):e419-e428. doi: 10.1016/S2468-2667(18)30135-X. Epub 2018 Aug 17. Lancet Public Health. 2018. PMID: 30122560 Free PMC article.
Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
Vaduganathan M, Claggett BL, Juraschek SP, Solomon SD. Vaduganathan M, et al. JAMA Cardiol. 2020 May 1;5(5):576-581. doi: 10.1001/jamacardio.2019.6192. JAMA Cardiol. 2020. PMID: 32101262 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information